This is the authors' abstract. We don't add key points for this paper.
The design and synthesis of a series of quinuclidine-containing spirooxazolidines (“spiroimidates”) and their utility as α7 nicotinic acetylcholine receptor partial agonists are described. Selected members of the series demonstrated excellent selectivity for α7 over the highly homologous 5-HT 3A receptor. Modification of the N -spiroimidate heterocycle substituent led to (1 S,2 R,4 S )- N -isoquinolin-3-yl)-4′ H -4-azaspiro[bicyclo[2.2.2]octane-2,5′oxazol]-2′-amine (BMS-902483), a potent α7 partial agonist, which improved cognition in preclinical rodent models.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cook et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: